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In this article, we will discuss how treatment strategies for myeloma have evolved and outline the challenges now faced following the
introduction of a number of novel active agents. In particular, we will focus on how achieving a maximum response and maintaining
such responses is becoming a key therapeutic strategy and how novel agents can be used to achieve this in the context of current
strategies such as autologous transplantation.
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Myeloma is a malignant disorder, which is characterised by an
excess of abnormal bone marrow plasma cells producing a clonal
paraprotein detectable in the serum and urine in the majority of
patients. Common clinical sequelae include lytic bone lesions,
fractures, myelosuppression and renal failure. It is a relatively
common disease with approximately 2500–3000 new cases each
year in the UK. The incidence increases with age, and the majority
of cases occur over the age of 60 years. With effective treatment,
the median survival is approximately 4 years. After years of few
therapeutic advances, we find ourselves standing at the site of a
marked expansion in treatment choices and the challenge now is
how to test these new treatments against the best previously
available.
Until recently, the basis of myeloma chemotherapy was aimed at
the achievement of a disease phase called ‘plateau’ where there is
an absence of overt clinical symptoms and paraprotein levels are
stable. Despite this aim, it was generally accepted that the quality
of life of patients in plateau phase was poor although a small
percentage of patients lived for a prolonged period with a relatively
good quality of life. With the advent of new agents that are able to
achieve better responses and outcomes, it has become increasingly
important to define the appropriate clinical settings and the
therapeutic strategies with which to use them. The clinical settings
are relatively easily recognised, including therapy for induction,
maintenance, relapse and refractory disease. In this article, we will
argue that the strategic aim with which to use novel treatments
should be to maximise clinical responses. This is based on what
has been learnt over the last 20 years and the clinical
characteristics of a complete response (CR), a disease phase where
there is a good quality of life and few ongoing symptoms.
Responses obtained should be maintained for the maximum time
period, which will require the development and implementation of
novel antimyeloma therapies suitable for the maintenance setting.
At present, the maximum number of CRs is achieved after high-
dose therapy (HDT) (Attal et al, 1996; Davies et al, 2001a; Child
et al, 2003), and the impact of new agents has to be compared to
this current gold standard. In this setting, it is important to
distinguish between agents that give good but transient responses
and those for which overall responses may be less but which may
be maintained for longer. Normally in myeloma treatment trials, it
is conventional to consider the impact of a single line of treatment
on overall survival (OS) as the major end point. However, it is
becoming increasingly apparent that during the average disease
course of a patient with myeloma, the patient will receive multiple
courses of treatment, the sequencing of which may or may not be
important. A good example of this is the observation of the
beneficial therapeutic effect of HDT whether it is used at
presentation or at relapse (Attal et al, 1996; Fermand et al, 1998;
Child et al, 2003). Consequently, it is important to distinguish the
end points of OS and progression free survival (PFS), both of
which can give useful information, and also recognise that OS may
be affected by subsequent treatment regimens.
THE DEVELOPMENT OF CURRENT TREATMENT
STRATEGIES
Initial myeloma trials showed that early death was, and still is, a
significant problem, and addressing the causes of this is important
including early diagnosis, the treatment of infection, hydration and
the choice of the most appropriate chemotherapy. Melphalan, an
alkylating agent, has been shown to be an effective treatment and
no evidence of a superior treatment regimen emerged in early
clinical trials, although it was shown in an early MRC trial that
single agent cyclophosphamide was equivalent to melphalan
(MRC, 1980). In the 1980s, several groups investigated the value
of using combination chemotherapy compared to single agent
melphalan. In the UK, the MRC Myeloma V trial compared
melphalan alone to ABCM (adriamycin, 1,3-bis (2-chloroethyl)-
1-nitrosourea (BCNU), cyclophosphamide and melphalan) and
showed a significant benefit for the combination, including
significant differences in achievement of plateau (61 vs 49%) and
in median OS (32 vs 24 months) (MacLennan et al, 1992).
However, systematic reviews of published and of individual patient
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advantage for other combinations (VMCP (vincristine, melphalan,
cyclophosphamide and prednisone), VBAP (vincristine, BCNU,
adriamycin and prednisone) and VCAP (vincristine, cyclopho-
sphamide, adriamycin and prednisone)) (MTCG, 1998), although
relatively few of these combinations included the use of an
anthracycline as in the ABCM regime.
At the same time, alternative combinations, dose schedules and
modes of administration of active chemotherapeutic agents were
being explored. High response rates were reported with dexa-
methasone alone and in combination with VAD in which
vincristine and adriamycin were given by a 4-day intravenous
infusion together with high-dose dexamethasone (Samson et al,
1989). Dexamethasone was recognised as a key component in this
regime, and good response rates were noted using this agent alone
but such responses were not maintained long term. A major
feature of this regimen is its lack of toxicity to the haematopoietic
stem cell compartment, making it an ideal regimen for use for stem
cell harvest before autologous transplantation. Concurrently,
investigators at the Royal Marsden Hospital looked at the role of
melphalan dose escalation. Doses of 140mgm
2 were found to
achieve high response rates, with CRs being reported in about 30%
of patients, and for the first time bone healing was noted
(McElwain and Powles, 1983). The development of autologous
stem cell rescue allowed safe escalation of the dose of melphalan to
200mgm
2 and resulted in even higher remission rates, with CR
being reported in approximately 50% of patients compared to the
very few CRs that were traditionally seen with standard dose
treatments such as oral melphalan. As a result of these clinical
investigations, a high-dose treatment strategy emerged, consisting
of VAD initially, to induce disease response, at which stage
haemopoietic stem cells are collected. These cells are then used to
support high-dose melphalan, which consolidates the responses
obtained. Analysis of the effect of response after HDT suggested
that patients achieving a CR had a better PFS and OS than those
who did not (Barlogie et al, 1999; Lahuerta et al, 2000; Davies et al,
2001a).
It became important, at this stage, to understand how the
intensive treatments aimed at achieving maximum response rates
compared to standard dose chemotherapies. The first of a series of
randomised trials was carried out by the Intergroupe Francophone
du Myelome (IFM) (Attal et al, 1996). In an intention to treat
analysis, they demonstrated a significant advantage for patients in
the intensive arm in terms of response rate, response duration and
survival, with a median OS of 56 months compared with 44 months
in the standard arm. The MRC Myeloma VII trial addressed the
same question, comparing ABCM with C-VAMP (cyclophospha-
mide, vincristine, adriamycin, methylprednisolone) followed by
high-dose melphalan (Child et al, 2003). A total of 400 patients
aged less than 65 years were randomised. There was a significant
improvement in OS of patients treated with intensive therapy
compared with those treated conventionally, with a median survival
of 54 months compared with 42 months. Response rates and
response durations were also improved in the HDT arm. A published
data meta-analysis of similar trials confirmed the beneficial
therapeutic effect of the intensive treatment approach, establishing
it as the standard treatment for suitable presenting patients.
Over the years, a number of maintenance strategies have been
investigated in order to prolong responses post-HDT and improve
quality of life. Interferon has been used in this setting but has not
been taken up widely on account of a number of features. It
significantly impaired quality of life, was expensive, and in meta-
analyses, although it was shown to be statistically significantly
better than no maintenance therapy, the benefit was not clinically
significant (MTCG, 2001). Dexamethasone has also been used, and
in a small study looked effective but again the side-effect profile
particularly in the elderly has not led to its general uptake
(Berenson et al, 2002). The therapeutic profile of a drug useful in
the maintenance setting is likely to be different from one used in
the induction phase of treatment, and while efficacy is important,
tolerability is crucial.
NOVEL TREATMENTS
To date, the majority of new agents have been tested in the relapse
and refractory setting in order to determine clinical efficacy and
safety profiles. Many of these agents are now being moved into
earlier disease stages where combination regimens based on in
vitro synergy can be tested. VAD is the classical treatment used to
achieve response before HDT. New therapies, working by
alternative mechanisms, incorporated into induction regimes prior
to transplant may improve the numbers of responses achieved
before transplant. They could also be used after transplant as part
of a strategy to maximise responses for patients who fail to achieve
a CR, if they did not induce severe myelosuppression. An
alternative to this approach, if the responses suggested in initial
studies are achieved, is that novel combinations could be used in
place of HDT. However, as HDT is recognised as an effective
regimen, it is still likely to be used at some stage of the disease
process. Before novel combinations can be compared with HDT in
a randomised setting as part of induction therapy, the response
rates and lengths of remission need to be firmly established;
however, such a comparison is tempting as intensive therapy
involves periods in hospital with a long period of recovery.
THALIDOMIDE AND ITS DERIVATIVES
The recognition that thalidomide was active in myeloma was based
on its antiangiogenic activity in in vitro models together with the
unexpected description of neo-angiogenesis in the bone marrow of
myeloma patients. Initial studies of single agent thalidomide in
relapsed refractory disease showed a remarkable 30% response
rate (Singhal et al, 1999). In vitro characterisation of its
mechanism of action demonstrated a variety of effects including
direct toxicity to the myeloma plasma cell, alteration in cytokine
secretion, interruption of the myeloma cell stromal cell interaction
and increase in T and NK cell activity (Hideshima et al, 2000;
Davies et al, 2001b). Thus, thalidomide is not a classical cytotoxic
providing a rationale for combining it with other treatments. The
addition of thalidomide to standard regimens for older less-fit
patients unsuitable for transplant options is of great clinical
interest. Complete responses with MP (melphalan and prednisone)
are in the order of 10%, but preliminary data using MPT
(melphalan, prednisone and thalidomide) suggest that these rates
can be increased to 50%, a level comparable to those achieved with
HDT (Palumbo et al, 2003). Current questions relate to whether
this improved response rate translates to improved survival and if
it does, the balance of standard vs intensive treatment may alter
and necessitate a specific randomised comparison.
Regimens have also been developed including combinations of
thalidomide and dexamethasone with or without cyclophospha-
mide (Rajkumar et al, 2002; Cavenagh and Oakervee, 2003; Weber
et al, 2003). These combinations represent an oral version of VAD
and have the potential to improve significantly pretransplant
responses, at the same time removing the need for an indwelling
catheter. An ongoing phase III study, MRC myeloma IX, is
comparing CTD (cyclophosphamide, thalidomide and dexametha-
sone) with CVAD (cyclophosphamide, vincristine, adriamycin and
dexamethasone). However, it seems highly likely that these new
regimes will be more effective and be associated with fewer side
effects than VAD and will become the new standard induction
therapy prior to HDT. Intensification of these regimes further by
the addition of other agents has been useful for refractory patients.
DT-PACE (dexamethasone, thalidamide, cisplatin, adriamycin,
cyclophosphamide, etoposide) has been developed for patients who
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HDT. This regimen is effective and able to rescue significant
numbers of patients who can then proceed to HDT (Lee CK et al,
2003). Whereas other maintenance strategies have not been widely
taken up, thalidomide maintenance for patients who have achieved
a response is appealing because of its multiple modes of action,
especially its immunomodulatory effect. It is currently being
explored in this setting, in particular looking at its side-effect
profile. A UKMF phase II study of 84 patients receiving
thalidomide maintenance post-HDT suggests that long-term
treatment is possible at low doses (o200mg) but that peripheral
neuropathy and other toxicities can affect its continued use (Feyler
et al, 2003). In spite of this down side, at a recent meeting in
Torino, preliminary results from the IFM suggest an improvement
in PFS when it is used following HDT. It is not unreasonable to
suggest that similar effects would be seen after treatment with oral
standard dose chemotherapy.
For this reason, thalidomide derivatives offer an interesting
alternative because of their favourable side-effect profiles. A
number of such derivatives of thalidomide including Revlimidt
and Actimidt have been developed, which potentially offer the
opportunity of a decrease in side effects (phocomelia, thrombosis,
peripheral neuropathy) with an increase in antimyeloma activity.
The immunomodulatory drugs (IMiDs) are 50000 times more
potent at inhibiting TNF secretion, more potent inducers of T-cell
proliferation with IFN and IL-2 secretion, and inhibitors of IL-1B
and IL-6 secretion, and in in vitro studies demonstrate an
increased myeloma cell kill (Hideshima et al, 2000). Initial phase
I and II studies of Revlimidt and Actimidt are extremely
encouraging with response rates between 38 and 58% with CRs in
the order of 10% and no significant somnolence, constipation or
neuropathy (Richardson et al, 2002, 2003a; Streetly et al, 2003). A
phase III randomised trial is ongoing.
BORTEZOMIB AND PROTEASOME INHIBITION
Bortezomib (Velcadet) is a boron-containing molecule, which
reversibly inhibits the proteasome. The 26S proteasome is a large
multi-subunit protein, which is present in all eukaryotic cells and
functions to degrade proteins targeted to it by ubiquitination.
Ubiquitinated proteins enter at one end of the proteasome and are
degraded to their individual peptides, which are shed from the far
end of its barrel-like structure. It consequently has a critical role in
maintaining intracellular homeostasis allowing complex intracel-
lular signalling events to take place, which are essential for the
control of cell cycle progression, transcription and apoptosis, as
well as mediating inter-cell signalling events such as those leading
to chemotaxis, angiogenesis and adhesion (Adams, 2004). Protea-
some inhibition with bortezomib can induce apoptosis even in
myeloma cell lines resistant to conventional chemotherapy,
suggesting that it works by a distinct mechanism not affected by
the drug resistance mechanisms leading to alkylator and steroid
resistance. One central mechanism by which Bortezomib functions
in myeloma is likely to be via inhibition of the breakdown of IkB
and consequently stabilisation of the NF-kB complex. This
prevents NF-kB translocation to the nucleus with consequent
inactivation of multiple downstream pathways. In addition, other
molecules stabilised by proteasome inhibition include p53, p21
and p27, and one possible mechanism of apoptosis is the
simultaneous accumulation of cell signalling and cell cycle
regulatory molecules. Bortezomib decreases the adhesion of the
myeloma plasma cell to stromal cells, which increases sensitivity to
apoptosis, as well as interrupts prosurvival paracrine and
autocrine cytokine loops in the bone marrow microenvironment
mediated by IL-6, IGF1, VEGF and TNFa (Hideshima et al, 2001).
A phase II study of 202 patients with relapsed refractory
myeloma demonstrated that 35% of these heavily pretreated
patients achieved a response to treatment and 10% had a CR or
near CR (Richardson et al, 2003b). These are truly remarkable
response rates for this late stage of the disease, suggesting that
even greater response rates would be seen earlier in the natural
history of the disease. The median survival was 16 months with a
median duration of response of 12 months. Response to treatment
was associated with improvement in a range of clinical parameters
and quality of life. A phase III trial has recently been closed early
due to the improved efficacy in disease free survival of bortezomib
over dexamethasone. Much like with thalidomide, bortezomib
combinations are being developed based on in vitro data (Ma et al,
2003). There is evidence for an additive effect with dexamethasone,
and this is supported by data from the phase II trial in which
patients who failed to respond to bortezomib alone showed
evidence of a response when dexamethasone was added. In vitro,a t
nontherapeutic doses, it has been possible to sensitise cell lines to
the cytotoxic effects of melphalan, doxorubicin and mitoxantrone
(Mitsiades et al, 2003). Ongoing clinical trials are using bortezomib
in combination with other agents, including melphalan, thalido-
mide and cyclophosphamide (Yang et al, 2003; Zangari et al, 2003).
These combinations may be particularly effective for refractory
disease and could potentially achieve greater response rates than
current high-dose treatment strategies and could be the subject of
randomised comparisons. It remains an open question as to the
stability of remissions induced by such combinations, and the
potential role of thalidomide/revlimidt maintenance needs to be
considered.
TARGETED TREATMENTS ON THE HORIZON
Targeted treatment is not a new concept and has in fact
underpinned strategies for treating cancer since their inception.
However, novel targeted approaches rely upon the identification of
a specific molecular target and the design of specific small
molecules to inhibit them. The activity of proteasome inhibition in
myeloma highlights the importance of protein checkpoints and
also points towards the importance of the unfolded protein
response in plasma cells (Lee AH et al, 2003). Indeed protein
synthesis may be the Achilles heel of the myeloma cell as it clearly
distinguishes plasma cells from many other cells within the body.
In this respect, it is not surprising that preclinical work evaluating
inhibitors of molecular chaperones using HSP90 inhibitors has
been shown to be effective in myeloma models. The study of
multistep models of cancer progression has suggested that in
addition to genetic changes such as translocation and loss of
heterozygosity, heritable epigenetic effects such as methylation of
CpG islands and modulation of chromatin structure via acetylation
of histone tails can lead to loss of expression of key genes and
disease progression. The key feature of these changes is that they
are amenable to therapeutic manipulation, which can result in
upregulation of gene expression associated with normalisation of
the cellular phenotype. Agents in clinical trial in myeloma include
the demethylating agents 5-azacytadine and decytabine and the
histone deacetylase inhibitors SAHA and LAQ.
As our understanding of the pathogenesis of myeloma improves,
the heterogeneity in outcome is becoming increasingly obvious.
Current prognostic factors such as B2M and more recently the
International Staging System (ISS) although effective are not
biologically based (Greipp et al, 2003). It is widely anticipated that
expression microarrays will identify patterns of gene expression,
which can be used to define outcome, identify targets and direct
treatment decisions. Perhaps the best examples of how to target
treatment rely upon defining a specific molecular lesion known to
be important. In myeloma, approximately 15% of patients harbour
the t(4;14), which deregulates the tyrosine kinase FGFR3 and can
be targeted using specific inhibitors. Inhibiting this is effective in
cell line models, but proof of concept in humans has not yet been
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the molecular characterisation of myeloma before selecting a
treatment, and would suggest that therapeutic approaches should
be tested in trials for specific molecular subtypes. In order to bring
this approach to fruition, it is important that we invest in the full
characterisation of the myeloma genome.
CONCLUSION
In the future, descriptions of myeloma currently characterised
by the statement ‘myeloma is an incurable disease’ will be replaced
by statements such as ‘myeloma is a highly treatable condition,
which is associated with prolonged survival and good quality of
life if the correct treatment decisions are made’. While this is
an accurate description of the current clinical situation, this
message has not yet fully reached the majority of physicians who
treat myeloma. Achieving the full advantage of these new
therapeutic options will rely upon making these approaches
available to all patients diagnosed with myeloma at an early stage
in the natural history of their disease. Making this possible will
involve education for general practitioners and hospital physicians
alike. In addition, once patients are diagnosed, equitable access to
novel therapeutics in an environment where the haemato-
oncologist using the drugs has adequate experience in their use
is also important and provides a strong argument for the
establishment of specialist clinics and centres that treat adequate
numbers of myeloma and can advise on the delivery of treatment.
The expansion of new therapeutics means that we have to develop
systems to evaluate and rapidly introduce agents shown to be
effective into the clinical arena. This demands a full interaction
between the pharmaceutical industry, clinicians and the regulatory
authorities.
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